Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.

Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987

Ahmed Elattar, Andrew Bryant, Brett A Winter-Roach, Mohamed Hatem, Raj Naik, Optimal primary surgical treatment for advanced epithelial ovarian cancer Cochrane Database of Systematic Reviews. ,vol. 2011, ,(2011) , 10.1002/14651858.CD007565.PUB2

Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, Philipp Harter, Isabelle Ray-Coquard, Jacobus Pfisterer, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. ,vol. 115, pp. 1234- 1244 ,(2009) , 10.1002/CNCR.24149

Michael Schemper, Terry L. Smith, A note on quantifying follow-up in studies of failure time Controlled Clinical Trials. ,vol. 17, pp. 343- 346 ,(1996) , 10.1016/0197-2456(96)00075-X

David A. Schoenfeld, Sample-size formula for the proportional-hazards regression model. Biometrics. ,vol. 39, pp. 499- 503 ,(1983) , 10.2307/2531021

Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Rustin, Florence Joly, Mansoor R Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh K B Parmar, Timothy J Perren, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial The Lancet Oncology. ,vol. 16, pp. 928- 936 ,(2015) , 10.1016/S1470-2045(15)00086-8

Richard Simon, Robert W. Makuch, A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder bias Statistics in Medicine. ,vol. 3, pp. 35- 44 ,(1984) , 10.1002/SIM.4780030106

TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, G Kristensen, MS Carey, P Beale, A Cervantes, C Kurzeder, A du Bois, J Sehouli, R Kimmig, A Stähle, F Collinson, S Essapen, C Gourley, A Lortholary, F Selle, MR Mirza, A Leminen, M Plante, D Stark, W Qian, AM Parmar, MK: Oza, ICON7 Investigators, None, A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. ,vol. 365, pp. 2484- 2496 ,(2011) , 10.1056/NEJMOA1103799

Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang, Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer The New England Journal of Medicine. ,vol. 365, pp. 2473- 2483 ,(2011) , 10.1056/NEJMOA1104390

Gennaro Daniele, Massimo Di Maio, Maria Carmela Piccirillo, Pasqualina Giordano, Ida Capuano, Sabrina Chiara Cecere, Jane Claire Bryce, Sandro Pignata, Francesco Perrone, None, New biological treatments for gynecological tumors: focus on angiogenesis Expert Opinion on Biological Therapy. ,vol. 14, pp. 337- 346 ,(2014) , 10.1517/14712598.2014.873401